Sangui Biotech International Stock Retained Earnings
SGBI Stock | USD 0 0.00 0.00% |
Sangui Biotech International fundamentals help investors to digest information that contributes to Sangui Biotech's financial success or failures. It also enables traders to predict the movement of Sangui Pink Sheet. The fundamental analysis module provides a way to measure Sangui Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sangui Biotech pink sheet.
Sangui |
Sangui Retained Earnings Analysis
Sangui Biotech's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Sangui Biotech Retained Earnings | (37 M) |
Most of Sangui Biotech's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangui Biotech International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Competition |
Based on the latest financial disclosure, Sangui Biotech International has a Retained Earnings of (37 Million). This is 103.97% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The retained earnings for all United States stocks is 100.4% higher than that of the company.
Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
All Next | Launch Module |
Sangui Fundamentals
Return On Asset | -0.64 | |||
Profit Margin | (1.27) % | |||
Operating Margin | (1.50) % | |||
Current Valuation | 1.68 M | |||
Shares Outstanding | 209.9 M | |||
Shares Owned By Insiders | 13.03 % | |||
Price To Earning | (18.33) X | |||
Price To Book | 46.44 X | |||
Price To Sales | 10.09 X | |||
Revenue | 69.19 K | |||
Gross Profit | 69.19 K | |||
EBITDA | (18.44 K) | |||
Net Income | (63.34 K) | |||
Cash And Equivalents | 30.47 K | |||
Total Debt | 48.9 K | |||
Debt To Equity | 0.05 % | |||
Current Ratio | 0.07 X | |||
Book Value Per Share | (0) X | |||
Cash Flow From Operations | (140.46 K) | |||
Beta | 0.22 | |||
Market Capitalization | 902.58 K | |||
Total Asset | 130.79 K | |||
Retained Earnings | (37 M) | |||
Net Asset | 130.79 K |
About Sangui Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sangui Biotech International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sangui Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sangui Biotech International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Check out Sangui Biotech Piotroski F Score and Sangui Biotech Altman Z Score analysis. Note that the Sangui Biotech Inter information on this page should be used as a complementary analysis to other Sangui Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Sangui Pink Sheet analysis
When running Sangui Biotech's price analysis, check to measure Sangui Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangui Biotech is operating at the current time. Most of Sangui Biotech's value examination focuses on studying past and present price action to predict the probability of Sangui Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangui Biotech's price. Additionally, you may evaluate how the addition of Sangui Biotech to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Money Managers Screen money managers from public funds and ETFs managed around the world |